Biography

Associate Professor Michele Teng is head of the Cancer Immunoregulation and Immunotherapy Laboratory at the QIMR Berghofer Medical Research Institute in Brisbane, Australia. She completed her PhD in 2006 at the Peter MacCallum Cancer Centre and University of Melbourne, Australia. Over her career, she has published 97 peer-reviewed primary papers and reviews (7952 citations, Google Scholar; H-index, 46) in high impact journals such as Cancer Discovery, Cancer Research, Nature Medicine, Nature Reviews Clinical Oncology and Lancet Oncology.

Her group is investigating how tumour-induced immune suppression impedes the effective treatment of established cancer. Specifically, she is interested in examining the role of T regulatory cells (Tregs), T-cell anergy/exhaustion, and the IL-23-associated cytokine family in the local tumour microenvironment using experimental and de novo models of cancer. In addition, her group is determining how scheduling of immunotherapies can further improve their antitumour efficacy and have developed a preclinical mouse model to assess how different combination therapies impact on tumour immunity and immune related adverse events. Achieving a better understanding of these immunosuppressive pathways, their relativity to one another and the diversity of effector pathways they control will enable the rational improvement of treatments for patients with established cancer.

https://www.qimrberghofer.edu.au/lab/cancer-immunoregulation-and-immunotherapy/